<DOC>
	<DOC>NCT02383966</DOC>
	<brief_summary>This trial aims to assess efficacy and safety of cetuximab when given in combination with chemotherapy compared with chemotherapy alone in Chinese subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) as the first-line treatment.</brief_summary>
	<brief_title>Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Subjects With Head and Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically or cytologically confirmed diagnosis of SCCHN Recurrent and/or metastatic SCCHN, not suitable for localregional treatment Presence of at least 1 measurable lesion according to RECIST Version 1.1 Signed written informed consent before any trialrelated activities are carried out Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Other protocoldefined inclusion criteria could apply Prior systemic chemotherapy, except if given as part of multimodal treatment for locally advanced disease, that was completed within 6 months before trial entry Surgery (excluding prior biopsy for diagnosis) or irradiation within 4 weeks before trial entry Previous treatment with monoclonal antibody or signal transduction inhibitors targeting epidermal growth factor receptor Nasopharyngeal carcinoma Known central nervous system metastasis and/or leptomeningeal disease Medical or psychological condition that would not permit the subject to complete the trial or sign informed consent Legal incapacity or limited legal capacity Other protocoldefined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>